Closed · RFA-CA-23-036 · CFDA 93.396 · Discretionary
Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $325K
- Award range
- Closed
- Status
- November 15, 2023
- Close date
- -
- Expected awards
The verdict
Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $325,000. Future funding cycles may be published under the same CFDA number.
- up to $325K
- award range
- Closed
- application status
- 93.396
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed) - is cataloged under number RFA-CA-23-036 and tied to CFDA assistance listing 93.396, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on July 17, 2023. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Up to $325,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on November 15, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $325,000
Close Date
November 15, 2023
Posted
July 17, 2023
Instrument
Cooperative Agreement
Description
NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the U01 mechanism to solicit applications focused on molecular mechanisms by which fusion oncoproteins drive pediatric cancers with the goals of better understanding the biology of these cancers and identifying potential drug targets or critical dependencies. Examples of relevant research activities include, but are not limited to, dissecting pathways by which these fusion oncoproteins cause cancer, characterizing the composition and structure of fusion oncoprotein complexes, and delineating the roles of ncRNAs and post-translational modifications in fusion oncoprotein function. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on pediatric solid tumors and brain tumors are particularly encouraged. U01 recipients will meet regularly with UM1 grantees funded through the Next Generation Chemistry Centers for Fusion Oncoproteins FOA.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |